

Almut G Winterstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5515182/publications.pdf>

Version: 2024-02-01

222
papers

5,720
citations

136950

32
h-index

98798

67
g-index

224
all docs

224
docs citations

224
times ranked

6718
citing authors

#	ARTICLE	IF	CITATIONS
1	Validity and reliability of measurement instruments used in research. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 2276-2284.	1.0	827
2	Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1411-1426.	1.9	325
3	Preventable Drug-Related Hospital Admissions. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1238-1248.	1.9	250
4	Nature of preventable adverse drug events in hospitals: a literature review. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 1750-1759.	1.0	227
5	Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 181-191.	2.9	213
6	Drug-Drug Interactions in the Elderly. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1675-1681.	1.9	175
7	Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. <i>Journal of Clinical Medicine</i> , 2019, 8, 989.	2.4	172
8	Improving the Well-Being of Elderly Patients via Community Pharmacy-Based Provision of Pharmaceutical Care. <i>Drugs and Aging</i> , 2001, 18, 63-77.	2.7	164
9	Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports. <i>American Journal of Health-System Pharmacy</i> , 2002, 59, 1742-1749.	1.0	121
10	Utilization of Pharmacologic Treatment in Youths with Attention Deficit/Hyperactivity Disorder in Medicaid Database. <i>Annals of Pharmacotherapy</i> , 2008, 42, 24-31.	1.9	113
11	Activated Partial Thromboplastin Time Versus Antifactor Xa Heparin Assay in Monitoring Unfractionated Heparin by Continuous Intravenous Infusion. <i>Annals of Pharmacotherapy</i> , 2011, 45, 861-868.	1.9	112
12	Cardiac Safety of Central Nervous System Stimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>Pediatrics</i> , 2007, 120, e1494-e1501.	2.1	108
13	Causes of hyperglycemia and hypoglycemia in adult inpatients. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 714-719.	1.0	83
14	Stimulants and Cardiovascular Events in Youth With Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2012, 51, 147-156.	0.5	78
15	Nature and causes of clinically significant medication errors in a tertiary care hospital. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 1908-1916.	1.0	75
16	Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications. <i>JAMA Pediatrics</i> , 2011, 165, 498.	3.0	75
17	Ambulatory Care: Efficacy and Safety of Oral Phenylephrine: Systematic Review and Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2007, 41, 381-390.	1.9	65
18	Institutional profile: University of Florida Health Personalized Medicine Program. <i>Pharmacogenomics</i> , 2017, 18, 421-426.	1.3	64

#	ARTICLE	IF	CITATIONS
19	Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. <i>BMJ</i> , The, 2012, 345, e4627-e4627.	6.0	59
20	Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 138, 959-964.	0.8	55
21	Cardiac Safety of Methylphenidate Versus Amphetamine Salts in the Treatment of ADHD. <i>Pediatrics</i> , 2009, 124, e75-e80.	2.1	50
22	Appropriateness of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Moderate-Preterm Infants. <i>JAMA Pediatrics</i> , 2013, 167, 1118.	6.2	50
23	Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1095-1105.	2.1	45
24	Defining pediatric polypharmacy: A scoping review. <i>PLoS ONE</i> , 2018, 13, e0208047.	2.5	42
25	<p>Impact of the Transition from ICDâ€“9â€“CM to ICDâ€“10â€“CM on the Identification of Pregnancy Episodes in US Health Insurance Claims Data</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1129-1138.	3.0	41
26	Determinants of Initial Pharmacological Treatment for Youths with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 187-195.	1.3	40
27	Body weight, frailty, and chronic pain in older adults: a cross-sectional study. <i>BMC Geriatrics</i> , 2019, 19, 143.	2.7	39
28	Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery. <i>Clinical Cardiology</i> , 2006, 29, 18-24.	1.8	38
29	Machine Learning in Drug Discovery and Development Part 1: A Primer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 129-142.	2.5	38
30	Patient counseling practices in U.S. pharmacies: Effects of having pharmacists hand the medication to the patient and state regulations on pharmacist counseling. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2011, 51, 527-534.	1.5	37
31	Pharmacoepidemiology of Antipsychotic Use in Youth with ADHD: Trends and Clinical Implications. <i>Current Psychiatry Reports</i> , 2013, 15, 382.	4.5	35
32	Opportunity for Genotypeâ€“Guided Prescribing Among Adult Patients in 11 US Health Systems. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 179-188.	4.7	35
33	Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. <i>JAMA Network Open</i> , 2020, 3, e2029411.	5.9	34
34	Quinolone Ear Drops After Tympanostomy Tubes and the Risk of Eardrum Perforation: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1052-1058.	5.8	33
35	Risk of Opioid Overdose Associated With Concomitant Use of Opioids and Skeletal Muscle Relaxants: A Populationâ€“Based Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 81-89.	4.7	33
36	Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 63-67.	2.5	32

#	ARTICLE	IF	CITATIONS
37	Characteristics of Older Adults Who Were Early Adopters of Medical Cannabis in the Florida Medical Marijuana Use Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1166.	2.4	32
38	Evaluation of Consumer Medication Information Dispensed in Retail Pharmacies. <i>Archives of Internal Medicine</i> , 2010, 170, 1317.	3.8	30
39	An In-Depth Analysis of Medication Errors in Hospitalized Patients with HIV. <i>Annals of Pharmacotherapy</i> , 2011, 45, 459-468.	1.9	29
40	Methods for external control groups for single arm trials or <sc>long-term</sc> uncontrolled extensions to randomized clinical trials. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1382-1392.	1.9	29
41	Palivizumab Utilization and Compliance: Trends in Respiratory Syncytial Virus Prophylaxis in Florida. <i>Journal of Pediatrics</i> , 2010, 156, 953-959.e1.	1.8	27
42	Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2013, 48, 874-884.	2.0	27
43	Sequential BART for imputation of missing covariates. <i>Biostatistics</i> , 2016, 17, 589-602.	1.5	27
44	Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker-Induced Lower-Extremity Edema With Loop Diuretics. <i>JAMA Network Open</i> , 2019, 2, e1918425.	5.9	27
45	Variation of the prevalence of pediatric polypharmacy: <sc>A</sc> scoping review. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 275-287.	1.9	26
46	<i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. <i>Journal of the American Heart Association</i> , 2022, 11, e024159.	3.7	24
47	Sex differences in patterns of prescription opioid non-medical use among 10-18-year olds in the US. <i>Addictive Behaviors</i> , 2019, 89, 163-171.	3.0	23
48	Sensorineural Hearing Loss Associated with Neomycin Eardrops and Nonintact Tympanic Membranes. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 148, 277-283.	1.9	22
49	Patient understanding of drug risks: an evaluation of medication guide assessments. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 518-525.	1.9	22
50	Trends in Antiepileptic Drug Use in Children and Adolescents With Epilepsy. <i>Pediatric Neurology</i> , 2017, 74, 32-40.	2.1	22
51	Prevalence of and Factors Associated With Long-term Concurrent Use of Stimulants and Opioids Among Adults With Attention-Deficit/Hyperactivity Disorder. <i>JAMA Network Open</i> , 2018, 1, e181152.	5.9	22
52	An algorithm to identify preterm infants in administrative claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 640-650.	1.9	21
53	Trends in prescription opioid use and dose trajectories before opioid use disorder or overdose in US adults from 2006 to 2016: A cross-sectional study. <i>PLoS Medicine</i> , 2019, 16, e1002941.	8.4	21
54	<p></p>Medical Costs and Productivity Loss Due to Mild, Moderate, and Severe Asthma in the United States<p></p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 545-555.	3.4	21

#	ARTICLE	IF	CITATIONS
55	An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 2012-2017.	3.0	21
56	Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1344-1352.	8.6	21
57	Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e744-e781.	2.2	21
58	Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. <i>BMC Medical Research Methodology</i> , 2012, 12, 119.	3.1	19
59	Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study. <i>Pediatrics</i> , 2016, 137, .	2.1	19
60	Prevalence of ADHD in Publicly Insured Adults. <i>Journal of Attention Disorders</i> , 2018, 22, 182-190.	2.6	19
61	A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019. <i>Medical Cannabis and Cannabinoids</i> , 2021, 4, 21-42.	3.3	19
62	Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study. <i>Journal of Affective Disorders</i> , 2018, 238, 542-546.	4.1	18
63	Association of US Food and Drug Administration Removal of Indications for Use of Oral Quinolones With Prescribing Trends. <i>JAMA Internal Medicine</i> , 2021, 181, 808.	5.1	18
64	Cardiovascular Safety of Stimulants in Children: Findings from Recent Population-Based Cohort Studies. <i>Current Psychiatry Reports</i> , 2013, 15, 379.	4.5	17
65	Antihypertensive Drug Class Interactions and Risk for Incident Diabetes: A Nested Caseâ€“Control Study. <i>Journal of the American Heart Association</i> , 2013, 2, e000125.	3.7	17
66	Consistency of psychotropic drugâ€“drug interactions listed in drug monographs. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 698-703.e2.	1.5	17
67	Development and validation of a complexity score to rank hospitalized patients at risk for preventable adverse drug events. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 1970-1984.	1.0	17
68	Establishing a Multidisciplinary Framework to Study Drugâ€“Drug Interactions of Hormonal Contraceptives: An Invitation to Collaborate. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 706-708.	2.5	17
69	Development and validation of an automated algorithm for identifying patients at high risk for drug-induced hypoglycemia. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1714-1728.	1.0	17
70	Randomization versus Real-World Evidence. <i>New England Journal of Medicine</i> , 2020, 383, e21.	27.0	17
71	Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. <i>Genetics in Medicine</i> , 2021, 23, 1185-1191.	2.4	17
72	Global covid-19 vaccine rollout and safety surveillanceâ€“how to keep pace. <i>BMJ, The</i> , 2021, 373, n1416.	6.0	17

#	ARTICLE	IF	CITATIONS
73	Uncontrolled Pain and Risk for Depression and Behavioral Symptoms in Residents With Dementia. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 2079-2086.e5.	2.5	17
74	Topical Dexamethasone and Tympanic Membrane Perforation Healing in Otitis Media. <i>Otology and Neurotology</i> , 2010, 31, 519-523.	1.3	16
75	Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 457-464.	1.9	16
76	A Bayesian Nonparametric Approach to Causal Inference on Quantiles. <i>Biometrics</i> , 2018, 74, 986-996.	1.4	16
77	Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease. <i>JAMA Pediatrics</i> , 2018, 172, 154.	6.2	16
78	Prevalence, Time Trends, and Utilization Patterns of Psychotropic Polypharmacy Among Pediatric Medicaid Beneficiaries, 1999-2010. <i>Psychiatric Services</i> , 2018, 69, 919-926.	2.0	16
79	Effectiveness of palivizumab prophylaxis in infants and children in Florida. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 53-60.	1.9	15
80	Internal validation of Medicaid Analytic eXtract (MAX) data capture for comprehensive managed care plan enrollees from 2007 to 2010. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1067-1076.	1.9	15
81	Stimulants Do Not Increase the Risk of Seizure-Related Hospitalizations in Children with Epilepsy. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 111-116.	1.3	15
82	Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering. <i>Journal of Clinical Hypertension</i> , 2019, 21, 825-834.	2.0	15
83	Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility. <i>Drug Safety</i> , 2020, 43, 329-338.	3.2	15
84	Polypharmacy in Attention Deficit Hyperactivity Disorder Treatment: Current Status, Challenges and Next Steps. <i>Current Psychiatry Reports</i> , 2012, 14, 447-449.	4.5	14
85	Trends of Neonatal Abstinence Syndrome Epidemic and Maternal Risk Factors in Florida. <i>Pharmacotherapy</i> , 2017, 37, 806-813.	2.6	14
86	Validation of algorithms to estimate gestational age at birth in the Medicaid Analytic eXtract-Quantifying the misclassification of maternal drug exposure during pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1414-1422.	1.9	14
87	Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: A retrospective cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 716-724.	1.9	14
88	Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107972.	2.3	14
89	Reply to discussion of "Empirical vs natural weighting in random effects meta-analysis". <i>Statistics in Medicine</i> , 2010, 29, 1272-1281.	1.6	13
90	Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate. <i>BMJ Quality and Safety</i> , 2020, 29, 636-644.	3.7	13

#	ARTICLE	IF	CITATIONS
91	Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies. American Journal of Obstetrics and Gynecology, 2022, 227, 263.e1-263.e38.	1.3	13
92	Rosiglitazone and the Risk of Adverse Cardiovascular Outcomes. Clinical Pharmacology and Therapeutics, 2011, 89, 776-778.	4.7	12
93	Otopical neomycin exposure in children with nonintact tympanic membranes. Laryngoscope, 2012, 122, 2529-2532.	2.0	12
94	Epidemiology of Persistent Tympanic Membrane Perforations Subsequent to Tympanostomy Tubes Assessed With Real World Data. Otology and Neurotology, 2016, 37, 1376-1380.	1.3	12
95	Pharmacometrics, Physiologically Based Pharmacokinetics , Quantitative Systems Pharmacology” What’s Next?”Joining Mechanistic and Epidemiological Approaches. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 352-355.	2.5	12
96	Medication safety infrastructure in critical-access hospitals in Florida. American Journal of Health-System Pharmacy, 2006, 63, 442-450.	1.0	11
97	Planning for pharmacy health information technology in critical access hospitals. American Journal of Health-System Pharmacy, 2007, 64, 315-321.	1.0	11
98	Effects of concomitant amiodarone and haloperidol on Q-Tc interval prolongation. American Journal of Health-System Pharmacy, 2008, 65, 2232-2236.	1.0	11
99	Associations between aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or coronary artery calcification: The Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. Atherosclerosis, 2013, 229, 310-316.	0.8	11
100	Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiology and Drug Safety, 2013, 22, 1036-1045.	1.9	11
101	Anti-diabetic drug utilization of pregnant diabetic women in us managed care. BMC Pregnancy and Childbirth, 2014, 14, 28.	2.4	11
102	Oxidation-state sensitive imaging of cerium dioxide by atomic-resolution low-angle annular dark field scanning transmission electron microscopy. Ultramicroscopy, 2016, 162, 52-60.	1.9	11
103	Risk for Tympanic Membrane Perforation After Quinolone Ear Drops for Acute Otitis Externa. Clinical Infectious Diseases, 2019, 70, 1103-1109.	5.8	11
104	Generalizability and accuracy of <sc>IBM MarketScan</sc> health risk assessment instrument data for augmentation of commercial claims data. Pharmacoepidemiology and Drug Safety, 2022, 31, 100-104.	1.9	11
105	An evaluation of the effects of gatifloxacin on glucose homeostasis. International Journal of Clinical Pharmacy, 2008, 30, 544-549.	1.4	10
106	Pharmacotherapy for incident attention-deficit/hyperactivity disorder: practice patterns and quality metrics. Current Medical Research and Opinion, 2014, 30, 1687-1699.	1.9	10
107	Clinical and Sociodemographic Factors Associated With Attention-Deficit/Hyperactivity Disorder in Patients With Cystic Fibrosis. Psychosomatics, 2015, 56, 495-503.	2.5	10
108	Impact of Schedule IV controlled substance classification on carisoprodol utilization in the United States: An interrupted time series analysis. Drug and Alcohol Dependence, 2019, 202, 172-177.	3.2	10

#	ARTICLE	IF	CITATIONS
109	Prevalence of Maternal Risk Factors Related to Neonatal Abstinence Syndrome in a Commercial Claims Database: 2011–2015. <i>Pharmacotherapy</i> , 2019, 39, 1005-1011.	2.6	10
110	Use of negative controls in a prescription sequence symmetry analysis to reduce <sc>time-varying</sc> bias. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1192-1199.	1.9	10
111	Validity of Laboratory-based Surveillance for Detection of Respiratory Syncytial Virus Seasons. <i>American Journal of Epidemiology</i> , 2013, 177, 841-851.	3.4	9
112	Identifying and characterizing preventable adverse drug events for prioritizing pharmacist intervention in hospitals. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 1774-1783.	1.0	9
113	Measurement of selected preventable adverse drug events in electronic health records: Toward developing a complexity score. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 1865-1877.	1.0	9
114	Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population-based cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 587-595.	1.9	9
115	Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis. <i>Pharmacotherapy</i> , 2019, 39, 912-920.	2.6	9
116	Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical and Translational Science</i> , 2020, 13, 473-481.	3.1	9
117	Utilization Patterns of Skeletal Muscle Relaxants Among Commercially Insured Adults in the United States from 2006 to 2018. <i>Pain Medicine</i> , 2021, 22, 2153-2161.	1.9	9
118	Quality of opioid prescribing in older adults with or without Alzheimer disease and related dementia. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 78.	6.2	9
119	Health-Related Quality of Life and Health Utilities of Mild, Moderate, and Severe Asthma: Evidence from the Medical Expenditure Panel Survey. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 929-941.	3.4	9
120	A Pharmacoepidemiologic Approach to Evaluate Real-world Effectiveness of Hormonal Contraceptives in the Presence of Drug-drug Interactions. <i>Epidemiology</i> , 2021, 32, 268-276.	2.7	9
121	Pharmacoeconomic Modeling of Nesiritide versus Dobutamine for Decompensated Heart Failure. <i>Pharmacotherapy</i> , 2006, 26, 34-43.	2.6	8
122	Azithromycin and Sensorineural Hearing Loss in Adults: A Retrospective Cohort Study. <i>Otology and Neurotology</i> , 2018, 39, 957-963.	1.3	8
123	Validation of mother-infant linkage using Medicaid Case ID variable within the Medicaid Analytic eXtract (MAX) database. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1222-1230.	1.9	8
124	Trends in prior receipt of prescription opioid or adjuvant analgesics among patients with incident opioid use disorder or opioid-related overdose from 2006 to 2016. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107600.	3.2	8
125	Development of a predictive model for drug-associated QT prolongation in the inpatient setting using electronic health record data. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 1059-1070.	1.0	8
126	Non-steroidal anti-inflammatory drug-associated acute kidney injury: does short-term NSAID use pose a risk in hospitalized patients?. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1409-1417.	1.9	8

#	ARTICLE	IF	CITATIONS
127	Using machine learning to identify diabetes patients with canagliflozin prescriptions at high risk of lower extremity amputation using real-world data. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 644-651.	1.9	8
128	Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: A population-based cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003921.	8.4	8
129	Pharmacy-specific quality indicators for asthma therapy. <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 430-445.	3.0	7
130	Nesiritide Following Maze and Mitral Valve Surgery. <i>Journal of Cardiac Surgery</i> , 2008, 23, 431-436.	0.7	7
131	Managed Care: Effect of an Academic Detailing Intervention on the Utilization Rate of Cyclooxygenase-2 Inhibitors in the Elderly. <i>Annals of Pharmacotherapy</i> , 2008, 42, 749-756.	1.9	7
132	ADHD treatment—supply or demand?. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 450-451.	1.9	7
133	Misclassification in assessment of diabetogenic risk using electronic health records. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 875-881.	1.9	7
134	Application of Multicategory Exposure Marginal Structural Models to Investigate the Association between Long-Acting Beta-Agonists and Prescribing of Oral Corticosteroids for Asthma Exacerbations in the Clinical Practice Research Datalink. <i>Value in Health</i> , 2015, 18, 260-270.	0.3	7
135	Development and validation of an automated algorithm for identifying patients at higher risk for drug-induced acute kidney injury. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 654-666.	1.0	7
136	Development and Validation of an Administrative Claims-based Measure for All-cause 30-day Risk-standardized Readmissions After Discharge From Inpatient Psychiatric Facilities. <i>Medical Care</i> , 2020, 58, 225-233.	2.4	7
137	Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 72-81.	1.9	7
138	Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case-control study. <i>PLoS Medicine</i> , 2022, 19, e1003947.	8.4	7
139	Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 146-155.	4.7	7
140	Watchful Waiting for Acute Otitis Media. <i>Pediatrics</i> , 2022, 150, .	2.1	7
141	Projecting the Effect of Nesiritide on Dialysis and Hospital Mortality in Cardiac Surgery Patients. <i>Value in Health</i> , 2010, 13, 643-648.	0.3	6
142	Psychotropic drug utilization in children with concurrent attention-deficit/hyperactivity disorder and anxiety. <i>Journal of Anxiety Disorders</i> , 2014, 28, 530-536.	3.2	6
143	Development of a refill pattern method to measure polypharmacy in administrative claims databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1407-1413.	1.9	6
144	Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 678-686.	1.9	6

#	ARTICLE	IF	CITATIONS
145	A transdisciplinary team approach to scoping reviews: the case of pediatric polypharmacy. BMC Medical Research Methodology, 2018, 18, 102.	3.1	6
146	Pain Assessments in MDS 3.0: Agreement with Vital Sign Pain Records of Nursing Home Residents. Journal of the American Geriatrics Society, 2019, 67, 2421-2422.	2.6	6
147	Concomitant Use of Quinolones and Stimulants and the Risk of Adverse Cardiovascular Symptoms: A Retrospective Cohort Study. Pharmacotherapy, 2019, 39, 1167-1178.	2.6	6
148	Performance of the Centers for Medicare & Medicaid Services'™ Opioid Overutilization Criteria for Classifying Opioid Use Disorder or Overdose. JAMA - Journal of the American Medical Association, 2019, 321, 609.	7.4	6
149	Psychotropic Treatment Pattern in Medicaid Pediatric Patients With Concomitant ADHD and ODD/CD. Journal of Attention Disorders, 2019, 23, 140-148.	2.6	6
150	Quality of Evidence Supporting Major Psychotropic Drug-Drug Interaction Warnings: A Systematic Literature Review. Pharmacotherapy, 2020, 40, 455-468.	2.6	6
151	Practice Patterns and Training Needs Among Physicians Certifying Patients for Medical Marijuana in Florida. Journal of Primary Care and Community Health, 2021, 12, 215013272110427.	2.1	6
152	Where to begin? Thirty must-read papers for newcomers to pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2022, 31, 257-259.	1.9	6
153	Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: group-based multi-trajectory models. Addiction, 2022, 117, 1982-1997.	3.3	6
154	PUK13 VALIDATION OF AUTOMATED DATABASE ALGORITHMS TO IDENTIFY HOSPITAL-ACQUIRED ACUTE RENAL FAILURE. Value in Health, 2004, 7, 366-367.	0.3	5
155	Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use. Evidence-Based Mental Health, 2012, 15, 43-43.	4.5	5
156	Physical Health Outcomes in Preschoolers with Prior Authorization for Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 833-839.	1.3	5
157	Determinants of Pharmacological Treatment Initiation and Persistence in Publicly Insured Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 2017, 37, 546-554.	1.4	5
158	Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration. Pharmacotherapy, 2019, 39, 1042-1052.	2.6	5
159	Sex differences in peer and parental risk factors for non-medical use of prescription opioids in youth. American Journal of Drug and Alcohol Abuse, 2020, 46, 203-215.	2.1	5
160	Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. Diabetes, Obesity and Metabolism, 2022, 24, 154-159.	4.4	5
161	Priorities for Medical Marijuana Research from the Perspective of Physicians, Dispensary Owners/Staff, and Patients: A Survey Study. Medical Cannabis and Cannabinoids, 2021, 4, 107-113.	3.3	5
162	Concurrent Use of Prescription Opioids and Gabapentinoids in Older Adults. American Journal of Preventive Medicine, 2022, 62, 519-528.	3.0	5

#	ARTICLE	IF	CITATIONS
163	Evaluation of a Beta-blocker “Edema” Loop Diuretic Prescribing Cascade: A Prescription Sequence Symmetry Analysis. <i>American Journal of Hypertension</i> , 2022, , .	2.0	5
164	Perioperative medication errors in otolaryngology. <i>Laryngoscope</i> , 2010, 120, 1214-1219.	2.0	4
165	Utilization of Alcohol Treatment Among HIV-Positive Women with Hazardous Drinking. <i>Journal of Substance Abuse Treatment</i> , 2016, 64, 55-61.	2.8	4
166	Prevalence of Psychotherapy Surrounding Initiation of Psychotropic Polypharmacy in the Medicaid-Insured Population, 1999–2010. <i>Psychiatric Services</i> , 2017, 68, 1120-1126.	2.0	4
167	A dynamic risk model for inpatient falls. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1293-1303.	1.0	4
168	Predicting medication-associated altered mental status in hospitalized patients: Development and validation of a risk model. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 953-963.	1.0	4
169	Development and validation of a dynamic inpatient risk prediction model for clinically significant hypokalemia using electronic health record data. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 301-311.	1.0	4
170	Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015. <i>Drug Safety</i> , 2021, 44, 447-454.	3.2	4
171	Clinical Conditions and Prescription Drug Utilization among Early Medical Marijuana Registrants in Florida. <i>Journal of Psychoactive Drugs</i> , 2021, 53, 185-194.	1.7	4
172	Agreement of Minimum Data Set 3.0 depression and behavioral symptoms with clinical diagnosis in a nursing home. <i>Aging and Mental Health</i> , 2021, 25, 1897-1902.	2.8	4
173	Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. <i>Diabetes Care</i> , 2022, 45, 1007-1012.	8.6	4
174	A tool kit for practice-based research. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 1607-1607.	1.0	3
175	Intensive Glucose Lowering and Cardiovascular Outcomes. <i>New England Journal of Medicine</i> , 2011, 364, 2263-2264.	27.0	3
176	Use of Systemic Antibiotics for Acute Otitis Externa: Impact of a Clinical Practice Guideline. <i>Otology and Neurotology</i> , 2018, 39, 1088-1094.	1.3	3
177	Common inpatient hypoglycemia phenotypes identified from an automated electronic health record-based prediction model. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 166-174.	1.0	3
178	An Interdisciplinary Team-Based Learning Experience in Ambulatory Patient Safety. <i>MedEdPORTAL: the Journal of Teaching and Learning Resources</i> , 0, , .	1.2	3
179	Discontinuation of Long-Term Opioid Therapy in Patients With Versus Without Dementia. <i>American Journal of Preventive Medicine</i> , 2022, 62, 270-274.	3.0	3
180	PCV23: A COST-BENEFIT MODEL FOR PERINDOPRIL IN SECONDARY STROKE PREVENTION. <i>Value in Health</i> , 2003, 6, 314-315.	0.3	2

#	ARTICLE	IF	CITATIONS
181	PRS17 COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB FROM THE PERSPECTIVE OF A SOUTHERN US MEDICAID AGENCY. <i>Value in Health</i> , 2009, 12, A301-A302.	0.3	2
182	Small Budget Impact Is a Result of Flawed Assumptions and Ignores Questionable Cost-Effectiveness for RSV Prophylaxis. <i>Value in Health</i> , 2010, 13, 684.	0.3	2
183	Authors'™ Responses In Response to the Letter From Ambrose. <i>Pediatrics</i> , 2014, 134, e1782-e1783.	2.1	2
184	Development of a Medication Safety and Quality Survey for Small Rural Hospitals. <i>Journal of Patient Safety</i> , 2017, 13, 249-254.	1.7	2
185	The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) 'EMA Joint Big Data Task Force. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1640-1641.	1.9	2
186	Commentary on: Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence. <i>Annals of Medicine</i> , 2019, 51, 97-98.	3.8	2
187	Appropriateness of Otic Quinolone Use among Privately Insured US Patients. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 162, 102-107.	1.9	2
188	Usability of encounter data for Medicaid comprehensive managed care vs traditional Medicaid fee-for-service claims among pregnant women. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 30-38.	1.9	2
189	Age of First Use of Prescription Opioids and Prescription Opioid Non-Medical Use among Older Adolescents. <i>Substance Use and Misuse</i> , 2020, 55, 2420-2427.	1.4	2
190	Redefining Resistant Hypertension. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e005979.	2.2	2
191	Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 317-325.	1.3	2
192	Uncontrolled Extensions of Clinical Trials and the Use of External Controls" Scoping Opportunities and Methods. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 187-199.	4.7	2
193	Triangulation of pharmacoepidemiology and laboratory science to tackle otic quinolone safety. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 75-80.	2.5	2
194	A systematic review of evidence for cannabis and cannabinoids as adjuvant therapy in palliative and supportive oncology care.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12091-12091.	1.6	2
195	Enhancing Quality Measurement With Clinical Information: A Use Case of Body Mass Index Change Among Children Taking Second Generation Antipsychotics. <i>Academic Pediatrics</i> , 2022, 22, S140-S149.	2.0	2
196	Perioperative Use of Gabapentinoids and Risk for Postoperative Long-Term Opioid Use in Older Adults Undergoing Total Knee or Hip Arthroplasty. <i>Journal of Arthroplasty</i> , 2022, 37, 2149-2157.e3.	3.1	2
197	Development of a Translational <scp>Exposure'Bracketing</scp> Approach to Streamline the Development of Hormonal Contraceptive Drug Products. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 909-916.	4.7	2
198	Automated medication error studies with audit supplementation were effectively designed and analyzed by time series. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 957-963.	5.0	1

#	ARTICLE	IF	CITATIONS
199	Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaidâ€”Reply. <i>JAMA Pediatrics</i> , 2012, 166, 968.	3.0	1
200	Clinical utility and perils of prescription drug monitoring programâ€”based alert systems. <i>Pain</i> , 2018, 159, 804-805.	4.2	1
201	Modelâ€”based standardization using an outcome model with random effects. <i>Statistics in Medicine</i> , 2019, 38, 3378-3394.	1.6	1
202	Medication Use for ADHD and the Risk of Driving Citations and Crashes Among Teenage Drivers: A Population-Based Cohort Study. <i>Journal of Attention Disorders</i> , 2020, 25, 108705472091576.	2.6	1
203	EFFECT OF HYDROCORTISONE VS. HYDROCORTISONE PLUS FLUDROCORTISONE ON MORTALITY IN CRITICALLY ILL PATIENTS.. <i>Critical Care Medicine</i> , 2005, 33, A168.	0.9	1
204	Response to Respiratory Syncytial Virus. <i>Southern Medical Journal</i> , 2008, 101, 212-213.	0.7	1
205	Manufacturer warnings of system-related medication errors. <i>American Journal of Health-System Pharmacy</i> , 2002, 59, 1110-1112.	1.0	0
206	PDB3 EVALUATION OF PHARMACIST INTERVENTIONS IN DIABETIC PATIENTS FROM RURAL COMMUNITY HEALTH CENTERS. <i>Value in Health</i> , 2004, 7, 337.	0.3	0
207	PRS47 SEASONAL VERSUS NEEDS-BASED IMMUNIZATION SCHEDULESâ€” THE EXAMPLE OF RSV. <i>Value in Health</i> , 2009, 12, A307.	0.3	0
208	Response to Letter to the Editor Regarding Sensorineural Hearing Loss Associated with Neomycin Eardrops and Nonintact Tympanic Membranes. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 148, 1061-1062.	1.9	0
209	Negative Results Do Not Imply Absence of Ototoxicity with Middle Ear Application of Neomycin. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 369-369.	1.9	0
210	RE: Drug risk assessment and data reuse. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 109-110.	1.9	0
211	Methods to Estimate Gestational Age Can Significantly Affect Study Resultsâ€”Reply. <i>JAMA Pediatrics</i> , 2014, 168, 388.	6.2	0
212	Comparison Of Rates Of Prescribing Oral Corticosteroids For Asthma Exacerbations Between Step-Down Therapy Approaches Among Initiators Of Inhaled Corticosteroids and Long-Acting Beta-Agonist Combination Therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB177.	2.9	0
213	Immeasurable Time Bias In Exposure to Ivacaftor. <i>Health Affairs</i> , 2019, 38, 328-328.	5.2	0
214	Letter by Alipour Haris et al Regarding Article, â€œMarijuana Use Among Young Adults (18â€”44 Years of) Tj ETQq0 0 0 rgBT /Overlock 51, e91.	2.0	0
215	Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2020, 75, e2-e5.	2.7	0
216	Introducing Commentary Series: â€œEvidence in Contextâ€” Medical Cannabis and Cannabinoids, 2021, 4, 1-2.	3.3	0

#	ARTICLE	IF	CITATIONS
217	Letter by Sarayani et al Regarding Article, "Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque". <i>Circulation</i> , 2021, 143, e1031-e1032.	1.6	0
218	Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2021;44:1344-1352. <i>Diabetes Care</i> , 2021, 44, e167-e167.	8.6	0
219	Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines. <i>European Journal of Pediatrics</i> , 2022, 181, 841-845.	2.7	0
220	WEIGHT-BASED HEPARIN PROTOCOLS ARE EFFICACIOUS BUT ARE THEY EFFECTIVE?. <i>Critical Care Medicine</i> , 2005, 33, A25.	0.9	0
221	INAPPROPRIATE USE OF VANCOMYCIN IN CRITICALLY ILL PATIENTS WITH AKI.. <i>Critical Care Medicine</i> , 2006, 34, A137.	0.9	0
222	1362. Antibiotic Prescribing for Acute Otitis Media in Commercially Insured Pediatric Patients in the United States. <i>Open Forum Infectious Diseases</i> , 2020, 7, S692-S692.	0.9	0